Recent developments include the company's Nasdaq debut, clinical progress updates on Nu-3 for diabetic foot ulcers, and data highlighting Nu-3's resistance profile supporting national action plans against antimicrobial resistance.

• Lakewood-Amedex debuted on Nasdaq under ticker LABT in April 2026, with the stock price rising following the listing [N4].
• In May 2026, the company provided a progress update on Nu-3 in diabetic foot ulcers, noting clinical developments though the stock declined following the announcement [N3].
• In July 2026, Lakewood-Amedex highlighted resistance data for Nu-3 supporting a national action plan addressing antimicrobial resistance, coinciding with a stock price increase [N2].
• Also in July 2026, the company was noted among top biotech gainers due to advances in Nu-3 progress, alongside other biotech stocks [N1].

The company has advanced its lead candidate Nu-3 through clinical development with data supporting its efficacy and resistance profile, which aligns with national action plans addressing antimicrobial resistance. Its strong liquidity position supports ongoing development activities. The appointment of an experienced biotech executive to the board and successful Nasdaq listing enhance corporate governance and access to capital markets. Continued clinical progress and regulatory engagement could strengthen its position in the antimicrobial therapeutics market.

As a smaller reporting biotech company, Lakewood-Amedex faces risks typical of early-stage clinical development, including clinical trial outcomes, regulatory approvals, and market adoption. The company reported a net loss and negative earnings per share for the latest quarter, reflecting ongoing development expenses without current product revenue. The competitive landscape for antimicrobial agents is challenging, and the company’s success depends on its ability to advance Nu-3 through clinical and regulatory milestones. Limited financial history and sector classification add to visibility challenges.

The company's moat is centered on its proprietary Bisphosphocin® compounds and the clinical development of Nu-3, which targets a significant unmet medical need in treating infected diabetic foot ulcers, a condition complicated by antimicrobial resistance. The intellectual property portfolio and clinical data supporting Nu-3 contribute to its competitive positioning in the antimicrobial therapeutics space. However, as a smaller reporting company with early-stage clinical assets, the moat is subject to typical biotech development and regulatory risks.

• Clinical Development Risk: The success of the company depends on the clinical development and regulatory approval of its lead candidate Nu-3, which is subject to inherent uncertainties and potential setbacks.
• Financial Risk: The company reported a net loss and negative earnings per share, indicating ongoing expenses without product revenue, which may require additional capital raising.
• Market and Competitive Risk: The antimicrobial therapeutics market is competitive, and the company must differentiate its products and navigate evolving resistance patterns and regulatory requirements.

• Lakewood-Amedex Biotherapeutics Inc. is a biotechnology company focused on developing Bisphosphocin® compounds, a novel class of fast-acting, broad-spectrum antimicrobials targeting drug-resistant infections and antimicrobial resistance.
• The company's lead clinical development program is Nu-3, a topically delivered antimicrobial gel for treating infected diabetic foot ulcers (iDFU).
• The company is publicly traded on The Nasdaq Stock Market under the ticker LABT.
• Lakewood-Amedex is classified as a smaller reporting company and an emerging growth company under SEC definitions.
• The company appointed Dr. Joseph Tucker to its Board of Directors in April 2026, who has extensive experience as a CEO and director in public biotechnology companies.
• As of June 30, 2026, the company reported cash and cash equivalents of approximately $2.58 million and short-term investments of $2.0 million, totaling about $4.58 million in liquid assets.
• Current assets as of June 30, 2026, were approximately $4.85 million, with current liabilities of about $0.63 million, resulting in a strong current ratio of 7.7 and a cash ratio of 7.29, indicating solid short-term liquidity.
• The company reported a net loss of approximately $3.77 million for the quarter ended June 30, 2026, with basic and diluted earnings per share of -$2.75.
• Recent news highlights include progress updates on Nu-3 in diabetic foot ulcers, resistance data supporting a national action plan, and the company's Nasdaq debut in April 2026.
• The company has disclosed an investor presentation dated July 15, 2026, detailing its Bisphosphocin® compounds, Nu-3 program, regulatory strategy, intellectual property, competitive landscape, and management team.